6-Oxo-6-[2-phenylethylamino]-3,E-hexenoic acid | 99425-96-4

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: 6-Oxo-6-[2-phenylethylamino]-3,E-hexenoic acid
• 英文别名: E-5-(2-phenylethylaminocarbonyl)pent-3-enoic acid；(E)-6-oxo-6-(2-phenylethylamino)hex-3-enoic acid
• CAS: 99425-96-4
• 化学式: C₁₄H₁₇NO₃
• 分子量: 247.294
• InChiKey: VUYKTQRPZSIRDB-SNAWJCMRSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  18
• 可旋转键数：
  7
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  66.4
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  氯甲酸乙酯 、 2-苯乙胺 在 三乙胺 作用下， 以 氯仿 为溶剂， 生成 6-Oxo-6-[2-phenylethylamino]-3,E-hexenoic acid
  参考文献：
  名称：

  Aromatic compounds

  摘要：

  描述了一种化合物的化学式I，其中X代表一个C2到8的烷基链，可选择地由一个双键或S(O).sub.n中断，其中n为0、1或2；Y代表O或NH，l和m各自独立地代表2、3或4，R.sub.10代表苯基，被一个或多个取代基R.sub.23取代，这些取代基可以相同也可以不同；或者R.sub.10代表吡啶基、饱和碳环基、烷基C 1到6或氢，R.sub.15代表氢或与R.sub.23一起形成(CH.sub.2).sub.p链，其中p代表0、1或2；R.sub.20、R.sub.21、R.sub.22和R.sub.23，这些可以相同也可以不同，独立地代表氢、烷基C 1到6、NHR.sub.25、SH、NO.sub.2、卤素、CF.sub.3、SO.sub.2 R.sub.30、CH.sub.2 OH或OH，其中R.sub.25代表氢、烷基C 1到6、烷酰基C 1到6或SO.sub.2烷基C 1到6，R.sub.30代表烷基C 1到6或NH.sub.2，条件是当X代表一个不间断的C4烷基链时，Y代表NH，m代表2，l代表2，R.sub.10代表苯基，R.sub.15代表氢，R.sub.21、R.sub.22和R.sub.23代表氢，那么R.sub.20不代表氢或4-OH，以及其药学上可接受的盐和溶剂化合物。还描述了一种制备化合物的方法和含有它们的药物组合物。该发明的化合物可用于治疗或预防肾功能衰竭或心血管疾病。

  公开号：

  US04883804A1

文献信息

• Substituted 3,4-dihydroxy phenylethylamino compounds
  申请人：Fisons plc

  公开号：US04922022A1

  公开（公告）日：1990-05-01

  Novel compounds of the formula ##STR1## in which one of R.sub.30 and R.sub.40 represents a substituted phenylalkyl group, the other of R.sub.30 and R.sub.40 represents hydrogen or halogen, and R.sub.50 and R.sub.60 each independently represent hydrogen or alkyl; in addition R.sub.60 may represent a substituted alkyl chain interrupted by N. The compounds of the invention are useful for the treatment or prophylaxis of renal failure or cardiovascular disease.

  公式为##STR1##的新化合物，其中R.sub.30和R.sub.40中的一个代表取代苯基烷基基团，另一个代表氢或卤素，R.sub.50和R.sub.60各自独立地代表氢或烷基；此外，R.sub.60还可以表示被N打断的取代烷基链。本发明的化合物可用于治疗或预防肾衰竭或心血管疾病。
• Aromatic compounds
  申请人：Fisons plc

  公开号：US04883804A1

  公开（公告）日：1989-11-28

  There are described compounds of formula I, ##STR1## in which X represents a C2 to 8 alkylene chain optionally interrupted by a double bond or by S(O).sub.n, wherein n is 0, 1 or 2; Y represents O or NH, l and m each independently represent 2, 3 or 4, R.sub.10 represents phenyl substituted by one or more substituents R.sub.23, which may be the same or different; or R.sub.10 represents pyridyl, a saturated carbocyclic group, alkyl C 1 to 6 or hydrogen, R.sub.15 represents hydrogen or together with R.sub.23 forms a (CH.sub.2).sub.p chain, wherein p represents 0, 1 or 2; R.sub.20, R.sub.21, R.sub.22 and R.sub.23, which may be the same or different, independently represent hydrogen, alkyl C 1 to 6, NHR.sub.25, SH, NO.sub.2, halogen, CF.sub.3, SO.sub.2 R.sub.30, CH.sub.2 OH or OH, wherein R.sub.25 represents hydrogen, alkyl C 1 to 6, alkanoyl C 1 to 6 or SO.sub.2 alkyl C 1 to 6, and R.sub.30 represents alkyl C 1 to 6 or NH.sub.2, provided that when X represents an uninterrupted C4 alkylene chain, Y represents NH, m represents 2, l represents 2, R.sub.10 represents phenyl, R.sub.15 represents hydrogen, and R.sub.21, R.sub.22 and R.sub.23 represent hydrogen, then R.sub.20 does not represent hydrogen or 4-OH, and pharmaceutically acceptable salts and solvates thereof. There are also described processes for the preparation of the compounds of formula I and pharmaceutical compositions containing them. The compounds of the invention may be used in the treatment or prophylaxis of renal failure or cardiovascular disorders.

  描述了一种化合物的化学式I，其中X代表一个C2到8的烷基链，可选择地由一个双键或S(O).sub.n中断，其中n为0、1或2；Y代表O或NH，l和m各自独立地代表2、3或4，R.sub.10代表苯基，被一个或多个取代基R.sub.23取代，这些取代基可以相同也可以不同；或者R.sub.10代表吡啶基、饱和碳环基、烷基C 1到6或氢，R.sub.15代表氢或与R.sub.23一起形成(CH.sub.2).sub.p链，其中p代表0、1或2；R.sub.20、R.sub.21、R.sub.22和R.sub.23，这些可以相同也可以不同，独立地代表氢、烷基C 1到6、NHR.sub.25、SH、NO.sub.2、卤素、CF.sub.3、SO.sub.2 R.sub.30、CH.sub.2 OH或OH，其中R.sub.25代表氢、烷基C 1到6、烷酰基C 1到6或SO.sub.2烷基C 1到6，R.sub.30代表烷基C 1到6或NH.sub.2，条件是当X代表一个不间断的C4烷基链时，Y代表NH，m代表2，l代表2，R.sub.10代表苯基，R.sub.15代表氢，R.sub.21、R.sub.22和R.sub.23代表氢，那么R.sub.20不代表氢或4-OH，以及其药学上可接受的盐和溶剂化合物。还描述了一种制备化合物的方法和含有它们的药物组合物。该发明的化合物可用于治疗或预防肾功能衰竭或心血管疾病。
• Substituted 3,4-dihydroxy-phenylethylamino compounds
  申请人：Fisons, plc

  公开号：US04720586A1

  公开（公告）日：1988-01-19

  There are provided compounds of formula I, ##STR1## in which R.sub.1 represents OH, R.sub.2 and R.sub.3, which may be the same or different, each independently represent hydrogen, fluorine, chlorine, bromine, alkyl C1 to 6, nitro, nitrile, (CH.sub.2).sub.p R.sub.9 or SR.sub.9, W represents a single bond, a 1,2; 1,3; or 1,4-disubstituted benzene ring; a --CH.dbd.CH--group or a 1,4-cyclohexanediyl group; X respresents NH, O, S, SO.sub.2, CO, CH.sub.2, CONH or --COO; Y represents (CH.sub.2)q, CO, CS, SO.sub.2 and R.sub.20 represents hydrogen, or Y represents CR.sub.15 R.sub.16 CR.sub.17 R.sub.18, wherein the carbon atom bearing R.sub.15 and R.sub.16 is adjacent to X and in which R.sub.15 and R.sub.18, together with the carbon atom to which they are attached form a carbonyl group, and R.sub.15, R.sub.16 and R.sub.20 each represent hydrogen, or R.sub.15 and R.sub.20 together form a chain --CH.sub.2 --, and R.sub.16, R.sub.17 and R.sub.18 each represent hydrogen, or R.sub.15, R.sub.16, R.sub.17 and R.sub.18 each independently represent hydrogen or alkyl C1 to 6 and R.sub.20 represents hydrogen; Z represents a single bond, NR.sub.19, CH.sub.2, O, CO, S or SO.sub.2, in which R.sub.19 represents hydrogen or alkyl C1 to 6; n, and m each independently represent an integer from 1 to 4 inclusive; q represents an integer from 1 to 3 inclusive; p represents 0 or an integer from 1 to 3 inclusive; R.sub.9 represents phenyl or phenyl substituted by hydroxy, and R.sub.10 represents hydrogen or chlorine, provided that (i) when R.sub.1 represents --OH, R.sub.2 and R.sub.3 both represent hydrogen, X represents NH, Y represents (CH.sub.2).sub.q, Z represents a single bond and R.sub.20 represents hydrogen, W does not represent a single bond; (ii) when R.sub.1 represents --OH, R.sub.2 and R.sub.3 both represent hydrogen, W represents a single bond, X represents NH and Z represents a single bond, then at least one of R.sub.15, R.sub.16, R.sub.17 and R.sub.18 is alkyl C1 to 6; (iii) when X represents SO.sub.2, CO, COO or CONH, then Y does not represent CO, CS or SO.sub.2 ; (iv) when Y represents CO, CS or SO.sub.2, then Z does not represent CO or SO.sub.2, and pharmaceutically acceptable derivatives thereof. There are also described the use of the compounds of formula I as pharmaceuticals, methods for making the compounds and pharmaceutical, e.g. cardiac, compositions containing the compounds.

  提供了化合物I的公式，其中R.sub.1代表OH，R.sub.2和R.sub.3可以相同或不同，各自独立地代表氢，氟，氯，溴，烷基C1至6，硝基，腈基，（CH.sub.2）.sub.pR.sub.9或SR.sub.9，W代表单键，1,2; 1,3;或1,4-二取代苯环；-CH.dbd.CH-基团或1,4-环己基基团；X代表NH，O，S，SO.sub.2，CO，CH.sub.2，CONH或-COO；Y代表（CH.sub.2）q，CO，CS，SO.sub.2和R.sub.20代表氢，或Y代表CR.sub.15 R.sub.16 CR.sub.17 R.sub.18，其中带有R.sub.15和R.sub.16的碳原子邻接X，且R.sub.15和R.sub.18与它们附着的碳原子一起形成羰基基团，且R.sub.15，R.sub.16和R.sub.20各代表氢，或R.sub.15和R.sub.20一起形成链-CH.sub.2-，R.sub.16，R.sub.17和R.sub.18各代表氢，或R.sub.15，R.sub.16，R.sub.17和R.sub.18各自独立地代表氢或烷基C1至6，R.sub.20代表氢；Z代表单键，NR.sub.19，CH.sub.2，O，CO，S或SO.sub.2，其中R.sub.19代表氢或烷基C1至6；n和m各自独立地代表从1到4的整数，包括1和4；q代表从1到3的整数；p代表0或从1到3的整数；R.sub.9代表苯基或被羟基取代的苯基，R.sub.10代表氢或氯，但是当R.sub.1代表-OH时，R.sub.2和R.sub.3都代表氢，X代表NH，Y代表（CH.sub.2）.sub.q，Z代表单键，R.sub.20代表氢时，W不代表单键；当R.sub.1代表-OH时，R.sub.2和R.sub.3都代表氢，W代表单键，X代表NH，Z代表单键时，至少有一个R.sub.15，R.sub.16，R.sub.17和R.sub.18是烷基C1至6；当X代表SO.sub.2，CO，COO或CONH时，Y不代表CO，CS或SO.sub.2；当Y代表CO，CS或SO.sub.2时，Z不代表CO或SO.sub.2，且其药学上可接受的衍生物。还描述了将公式I的化合物用作制药物的用途，制备化合物和制药，例如心脏，含有化合物的组合物。
• Dihydroxy-phenethylamino compounds useful as pharmaceuticals
  申请人：Fisons, plc

  公开号：US04803225A1

  公开（公告）日：1989-02-07

  There are provided compounds of formula I, ##STR1## and pharmaceutically acceptable derivatives thereof. There are also described the use of the compounds of formula I as pharmaceuticals, methods for making the compounds and pharmaceutical, e.g. cardiac, compositions containing the compounds.

  提供了公式I的化合物，##STR1##以及其药学上可接受的衍生物。还描述了公式I化合物作为药物的用途，制备化合物和制药方法，例如含有这些化合物的制药，如心脏组成物。
• 3,4-Dihydroxyphenylethylamine derivatives and their use
  申请人：Fisons plc

  公开号：US04885313A1

  公开（公告）日：1989-12-05

  Novel 3,4-dihydroxyphenylethylamine derivatives possess dopaminergic activity in animals and are therefore useful in the treatment of iner alia congestive heart failure, renal failure and reversible obstructive airways disease. The compounds are generally administered in the form of a pharmaceutical composition comprising the active ingredient in admixture with a pharmaceutically acceptable adjuvant, diluent or carrier.

  小说3,4-二羟基苯乙胺衍生物具有动物多巴胺活性，因此在治疗充血性心力衰竭、肾功能衰竭和可逆性阻塞性气道疾病方面非常有用。这些化合物通常以药物组成物的形式给予，其中包括与药理学上可接受的辅料、稀释剂或载体混合的活性成分。